Variants on ESR1 and their Association with Prostate Cancer Risk: A Meta-analysis

Ding, Xiang; Cui, Feng-Mei; Xu, Song-Tao; Pu, Jin-Xian; Huang, Yu-Hua; Zhang, Jiang-Lei; Wei, Xue-Dong; Hou, Jian-Quan; Yan, Chun-Yin

추천

검색

자료유형: 학술저널

저자정보: Ding, Xiang (Department of Urology, the First Affiliated Hospital of Soochow University) Cui, Feng-Mei (Department of Toxicology, School of Radiation Medicine and Public Health, Soochow University) Xu, Song-Tao (Department of Urology, the First People's Hospital of Taicang) Pu, Jin-Xian (Department of Urology, the First Affiliated Hospital of Soochow University) Huang, Yu-Hua (Department of Urology, the First Affiliated Hospital of Soochow University) Zhang, Jiang-Lei (Department of Urology, the First Affiliated Hospital of Soochow University) Wei, Xue-Dong (Department of Urology, the First Affiliated Hospital of Soochow University) Hou, Jian-Quan (Department of Urology, the First Affiliated Hospital of Soochow University) Yan, Chun-Yin (Department of Urology, the First Affiliated Hospital of Soochow University)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제13권 제8호

발행연도: 2012.1

수록면: 3,931 - 3,936 (6page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Background: Epidemiological studies evaluating the association of two variants rs9340799 and rs2234693 on estrogen receptor 1 (ESR1) with prostate risk have generated inconsistent results. Methods: A meta-analysis was here conducted to systematically evaluate the relationship of these two variants with prostate cancer susceptibility. Results: For rs9340799, heterozygosity of T/C carriers showed a significant increased prostate cancer risk with a pooled odds ratio (OR) of 1.34 (95% CI = 1.06-1.69) while homozygote C/C carriers showed an increased but not statistically significant association with prostate cancer risk (pooled OR = 1.29, 95% CI = 0.94-1.79). Compared to the homozygous TT carriers, the allele C carriers showed a 31% increased risk for prostate cancer (pooled OR = 1.31, 95% CI = 1.06-1.63). No significant association between the rs2234693 and prostate cancer risk was found with the pooled OR of 1.15 (95% CI = 0.97-1.39, T/C and C/C vs. T/T) under the dominant genetic model. Compared to the homozygote T/T carriers, the heterozygous T/C carriers did not show any significantly different risk of prostate cancer (pooled OR = 1.13, 95% CI = 0.94-1.36) and the homozygous C/C carriers also did not show a significant change for prostate cancer risk compared to the wide-type T/T carriers (pooled OR = 1.26, 95% CI = 0.98-1.62). Conclusion: These data suggested that variant rs9340799, but not rs2234693, on ESR1 confers an elevated risk of prostate cancer.

#ESR1 #prostate cancer #polymorphisms #meta-analysis

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요